Harrow has relaunched Triesence, an FDA-approved, preservative-free corticosteroid used in eye surgeries and to treat severe ocular inflammation, according to a company press release.
Triesence had been absent from the market for over 5 years, appearing on the FDA Drug Shortage List and facing 2 years of inventory depletion.
“We are very excited to have brought Triesence back to the U.S. market,” Mark L. Baum, CEO of Harrow said in the press release, noting the extensive global collaboration required to rebuild the product’s supply chain.
With the relaunch, surgeons can once again use Triesence to enhance visibility during vitrectomies. The suspension provides a clear white backdrop against the retina, making it easier to identify pathologic membranes.
Dr. Rishi Singh, an ophthalmologist and vitreoretinal surgeon at Cleveland Clinic Florida, highlighted the importance of TRIESENCE in clinical practice: “An FDA-approved, preservative-free corticosteroid is critical for office-based and surgical procedures… its absence left many ophthalmologists without a reliable alternative.”
Read the full press release here.
Related Content
